QSAM Biosciences Appoints Richard K. Burt, M.D., Pioneer in the Use of Stem Cell Transplants to Treat Autoimmune Diseases, to Scientific Board of Advisors
April 28, 2021 09:00 ET
|
QSAM Biosciences Inc.
Austin, TX, April 28, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation nuclear medicines for the treatment of cancer and related diseases, announced...
QSAM Biosciences Issues Letter from CEO on Successful Achievements and Future Milestones for Company
April 19, 2021 09:00 ET
|
QSAM Biosciences Inc.
Austin, TX, April 19, 2021 (GLOBE NEWSWIRE) -- The Chief Executive Officer of QSAM Biosciences Inc. (OTCQB: QSAM), Douglas Baum, provided the following letter to shareholders today: Dear...
QSAM Biosciences Seeks to Expand Radiochemical Assets; Signs Option Agreement to License its Second Promising Cancer Therapy
March 17, 2021 09:00 ET
|
QSAM Biosciences Inc.
Austin, Texas, March 17, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences, Inc. (OTCQB: QSAM) announced today that it has signed an Exclusive Option Agreement with IsoTherapeutics Group, LLC to allow the...
QSAM Biosciences Appoints Charles J. Link, Jr., M.D., Experienced Biotech Executive and Innovator, to Board of Directors
February 16, 2021 09:00 ET
|
QSAM Biosciences Inc.
Austin, TX, Feb. 16, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation nuclear medicines for the treatment of cancer and related diseases, announced...
QSAM Biosciences Clarifies Recent Promotional and Trading Activities at the Request of OTC Markets
February 11, 2021 18:08 ET
|
QSAM Biosciences Inc.
Austin, Texas;, Feb. 11, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM) (“QSAM” or the “Company”), today announced that it became aware on February 9, 2021 of certain promotional...
QSAM Biosciences Closes Series B Preferred Private Placement; $2.5 Million in New Capital to Fund Upcoming Clinical Trials
January 28, 2021 09:00 ET
|
QSAM Biosciences Inc.
Austin, Texas, Jan. 28, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation nuclear medicines for the treatment of cancer and related diseases,...
QSAM Biosciences Receives Favorable Safety Results in Study for its Leading Radiopharmaceutical Drug Candidate
January 21, 2021 09:00 ET
|
QSAM Biosciences Inc.
Palm Beach, FL, Jan. 21, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next generation nuclear medicines for the treatment of cancer and related diseases and...
QSAM Biosciences Receives Notice of Allowance for European Patent and Expands Licensed IP Portfolio
December 10, 2020 09:00 ET
|
QSAM Biosciences Inc.
Palm Beach, FL, Dec. 10, 2020 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next generation nuclear medicines, including Cyclosam® Samarium-153-DOTMP, for the...
QSAM Biosciences Issues Letter from New CEO; Presents Opportunities Ahead for Company
November 24, 2020 09:00 ET
|
QSAM Biosciences Inc.
Palm Beach, FL, Nov. 24, 2020 (GLOBE NEWSWIRE) -- The recently appointed Chief Executive Officer of QSAM Biosciences Inc. (OTCQB: QSAM), Douglas Baum, provided in the following letter to...
QSAM Biosciences Advances Plan of Separation from Legacy Business
November 10, 2020 09:00 ET
|
QSAM Biosciences Inc.
Pharmaceutical Industry Experts Assume Leadership Roles at QSAM;Over $4M in Debt Eliminated from Balance Sheet Palm Beach, FL, Nov. 10, 2020 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM)...